Monthly information on share capital and company voting rights

Rhea-AI Summary

Cellectis, a clinical-stage biopharmaceutical company, focuses on developing allogeneic CAR-T immunotherapies for cancer treatment. As of March 31, 2021, the firm reports a total of 43,039,180 shares in capital and 49,104,029 voting rights. The company aims to provide life-saving UCART product candidates to address cancers like acute myeloid leukemia and multiple myeloma. With over 21 years of expertise in gene editing, Cellectis utilizes TALEN® technology and PulseAgile electroporation to create ready-to-use gene-edited CAR T-cells.

Positive

• Cellectis has developed an innovative allogeneic CAR-T approach for cancer treatment.
• Strong commitment to addressing unmet medical needs in oncology, including cancers like AML and MM.
• The company leverages over 21 years of expertise in gene editing technology.

Negative

• None.

(Article 223-16 of General Regulation of the French financial markets authority)

NEW YORK, April 12, 2021 (GLOBE NEWSWIRE) --

Listing market: Euronext Growth

ISIN code: FR0010425595

Date	Total number of shares in the capital	Total number of voting rights
03/31/2021	43,039,180	49,104,029

About Cellectis
Cellectis is developing the first of its kind allogeneic approach for CAR-T immunotherapies in oncology, pioneering the concept of off-the-shelf and ready-to-use gene-edited CAR T-cells to treat cancer patients. As a clinical-stage biopharmaceutical company with over 21 years of expertise in gene editing, Cellectis is developing life-changing product candidates utilizing TALEN^®, its gene editing technology, and PulseAgile, its pioneering electroporation system to harness the power of the immune system in order to target and eradicate cancer cells.

As part of its commitment to a cure, Cellectis remains dedicated to its goal of providing life-saving UCART product candidates to address unmet needs for multiple cancers including acute myeloid leukemia (AML), B-cell acute lymphoblastic leukemia (B-ALL) and multiple myeloma (MM).

Cellectis headquarters are in Paris, France, with additional locations in New York and Raleigh, North Carolina. Cellectis is listed on the Nasdaq Global Market (ticker: CLLS) and on Euronext Growth (ticker: ALCLS). For more information, visit www.cellectis.com.

Follow Cellectis on social media: @cellectis, LinkedIn and YouTube.

TALEN^® is a registered trademark owned by Cellectis.

For further information, please contact:

Media contacts:
Pascalyne Wilson, Communications Manager, +33776991433, media@cellectis.com

IR contact:
Simon Harnest, SVP, Corporate Strategy and Finance, 646-385-9008, simon.harnest@cellectis.com

Attachment

• Voting_Rights_PR_March_EN_docx

FAQ

What is the current number of shares for Cellectis as of March 31, 2021?

Cellectis has a total of 43,039,180 shares in capital.

How many voting rights does Cellectis have as of March 31, 2021?

Cellectis has a total of 49,104,029 voting rights.

What types of cancers is Cellectis targeting with its UCART product candidates?

Cellectis is targeting acute myeloid leukemia, B-cell acute lymphoblastic leukemia, and multiple myeloma.

What technology does Cellectis use for gene editing?

Cellectis utilizes TALEN® technology for gene editing.

On which stock exchanges is Cellectis listed?

Cellectis is listed on the Nasdaq Global Market under ticker CLLS and on Euronext Growth under ticker ALCLS.